This project will examine the relation of oligomeric and fibrillar amyloid-p (AP) species with changes in postsynaptic dendritic spines and pre-synaptic axonal terminals within the cortical default mode network (DMN) over the clinical progression of Alzheimer's disease (AD). To gain greater insight into the structural basis of functional deficits and how they relate to amyloid pathology in these regions, we propose to quantify AB and synaptic changes in postmortem brain tissues from subjects with no cognitive impairment (NCI), mild cognitive impairment (MCI), or early AD. We will divide NCI subjects into low/no pathology (LP-NCl) and high pathology (HP-NCl) groups which are considered to be preclinical AD cases, to examine synaptic changes in the presence of AB at the earliest stages of the disease. AB analyses will target oligomeric AB in the synaptosomal compartment, and N-terminus truncated and pyroglutamate modified (NpE) AB. Spatial relation of synaptic markers with oligomeric and NpE AB deposits will be analyzed by confocal microscopy. To complete our proposed Aims, first we will quantify concentrations of oligomeric and NpE AB in whole tissue homogenate and synaptosome fraction from DMN regions (Aim 1). We will also correlate these changes with neuropathology (e.g. tau) of the cholinergic basal forebrain neurons which project to these cortical areas and are studies in subprojects 1 and 3.
In Aim 2, dendritic spine density will be quantified, by complementary analyses of a post-synaptic protein biochemical assay and confocal microscopy in tissue sections, and correlated with variables quantified in Aim 1.
Aim 3 will quantify cholinergic, glutamatergic, and GABAergic terminals in DMN regions to determine how they change relative to increased oligomeric AB in synaptosomes, NpE AB, PiB binding, and to changes in dendritic spines in HP-NCl, MCI, and AD. Elucidation ofthe histopathological and biochemical signatures of clinical transitions from preclinical to MCI to AD will guide development of novel diagnostic imaging and therapic agents.
Alzheimer's disease is a major cause of dementia in the elderly, and currently there is no effective treatment. The proposed studies will examine subjects in the earliest stages of the disease and will shed new light on the role of amyloid pathology in the brain and its relation to a progressive impairment of neuronal communications and declining memory function in these people.
|Perez, Sylvia E; He, Bin; Nadeem, Muhammad et al. (2015) Resilience of precuneus neurotrophic signaling pathways despite amyloid pathology in prodromal Alzheimer's disease. Biol Psychiatry 77:693-703|
|Alldred, Melissa J; Lee, Sang Han; Petkova, Eva et al. (2015) Expression profile analysis of vulnerable CA1 pyramidal neurons in young-Middle-Aged Ts65Dn mice. J Comp Neurol 523:61-74|
|Alldred, Melissa J; Lee, Sang Han; Petkova, Eva et al. (2015) Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of Down syndrome (DS) and Alzheimer's disease (AD). Brain Struct Funct 220:2983-96|
|Counts, Scott E; Alldred, Melissa J; Che, Shaoli et al. (2014) Synaptic gene dysregulation within hippocampal CA1 pyramidal neurons in mild cognitive impairment. Neuropharmacology 79:172-9|
|Counts, Scott E; Ray, Balmiki; Mufson, Elliott J et al. (2014) Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease. J Clin Immunol 34 Suppl 1:S80-5|
|Ash, Jessica A; Velazquez, Ramon; Kelley, Christy M et al. (2014) Maternal choline supplementation improves spatial mapping and increases basal forebrain cholinergic neuron number and size in aged Ts65Dn mice. Neurobiol Dis 70:32-42|
|Hales, Chadwick M; Dammer, Eric B; Diner, Ian et al. (2014) Aggregates of small nuclear ribonucleic acids (snRNAs) in Alzheimer's disease. Brain Pathol 24:344-51|
|Yan, Jian; Ginsberg, Stephen D; Powers, Brian et al. (2014) Maternal choline supplementation programs greater activity of the phosphatidylethanolamine N-methyltransferase (PEMT) pathway in adult Ts65Dn trisomic mice. FASEB J 28:4312-23|
|Hales, Chadwick M; Seyfried, Nicholas T; Dammer, Eric B et al. (2014) U1 small nuclear ribonucleoproteins (snRNPs) aggregate in Alzheimer's disease due to autosomal dominant genetic mutations and trisomy 21. Mol Neurodegener 9:15|
|James, Bryan D; Leurgans, Sue E; Hebert, Liesi E et al. (2014) Contribution of Alzheimer disease to mortality in the United States. Neurology 82:1045-50|
Showing the most recent 10 out of 176 publications